


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds formula I



in which

A denotes a mono- or bicyclic aromatic or non-aromatic carba- or heterocyclic ring system which is unsubstituted or mono- or poly-substituted by R<sup>1</sup>,

R<sub>1</sub> denotes H, Hal, NO<sub>2</sub>, NHR, NRR, OR, CO-R, SO<sub>3</sub>R, SO<sub>2</sub>R, SR, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>14</sub> cycloalkyl,

R<sub>2</sub> denotes H, Hal, NO<sub>2</sub>, NHR, NRR, OR, CO-R, SO<sub>3</sub>R, SO<sub>2</sub>R, SR, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>14</sub> cycloalkyl,

R<sub>3</sub> denotes C<sub>1</sub>-C<sub>8</sub> alkyl,

X denotes CO, CS, SO<sub>2</sub>,

Y denotes a single bond, O, NH, CH<sub>2</sub>

R denotes H or a C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>14</sub> cycloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl or C<sub>7</sub>-C<sub>14</sub> aralkyl group, which may be mono- or polysubstituted by R<sub>5</sub> and whose alkyl-C chain may be interrupted by -O-,

Hal denotes F, Cl, Br, or I


m denotes 0, 1, 2, 3 or 4

and

n denotes 0, 1, 2 or 3,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, exclusively mixtures thereof in all ratios.

2. (Original) Compounds of the formula IA



in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, Y, A, m and n have the meaning indicated in Claim 1, and pharmacological usable derivatives, salts, solvates and stereoisomers thereof and mixtures thereof in all ratios.

3. (Currently Amended) Compound of the formula I and IA, according to Claim 1 or 2 in which

A denotes phenyl, pyridyl, thienyl or cyclohexyl, each of which is unsubstituted or mono- or polysubstituted by R<sup>1</sup>,

R<sup>1</sup> denotes H

R<sup>2</sup> denotes H or Hal.

4. (Currently Amended) Medicament of the formula I according to one or more of Claims 1, 2 or 3 Claim 1 in which

A denotes phenyl or naphthyl

and/or

X denotes CO or SO<sub>2</sub>

and/or

Y denotes a single bond or NH.

5. (Currently Amended) Use of the compounds of the formula I and/or IA according to ~~Claims 1-4~~ Claim 1 and physiologically acceptable salts, solvates and derivatives thereof for the preparation of medicaments for the treatment and/or prophylaxis of irritable bowel syndrome.
6. (Currently Amended) Pharmaceutical composition, characterised by a content of at least one compound of the formula I and/or IA and/or one of its physiologically acceptable salts, solvates and derivatives according to ~~one of~~ Claims 1 to 4 Claim 1 for the treatment and/or prophylaxis of irritable bowel syndrome.
7. (Currently Amended) Compounds of the formula I according to Claim 1 to 4 and acceptable salts, solvates and derivatives thereof as medicaments.
8. (Currently Amended) Use of the compounds of the formula I and/or IA according to Claim 1 to 4 and physiologically acceptable salts, solvates and derivatives thereof for the preparation of medicaments for the treatment and/or prophylaxis of diseases which can be influenced by kappa agonists.
9. (Currently Amended) Medicament formulation comprising at least one compound of the formula I and or IA according to ~~one or more of the preceding claims~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.